The Competition Commission of India, based on a positive prima facie determination on contravention of Section 4(2)(c) of the Competition Act, ordered investigation against pharma major Roche with respect to the cancer drug, Trastuzumab. The complaint was filed by Biocon and Mylan Pharmaceuticals. Highlights of order The commission is of considered opinion that the [...]
After the news that Novartis failed to secure an Indian patent for Glivec, the patenting woes of Western pharma in India seem to continue as Merck are denied interim relief in a patent case against Glenmark. The decision came within days of Merck’s subsidiary, MSD India, dragging the domestic company to court over the [...]
Post Novartis Glivec case ruling competition between MNC pharmaceuticals & Indian generic companies gets fierce as US based Merck Sharp & Dohme (MSD), the third largest pharma company by revenues , has filed a patent infringement suit with Delhi High court against domestic generic company Glenmark Pharmaceuticals. MSD move comes a week after Glenmark [...]
India’s Supreme Court has set an important precedent in refusing to grant a patent to Novartis for an updated version of its cancer drug Glivec. The verdict will allow generic drug makers within the country to continue selling cheap versions of the drug, which is used to treat chronic myeloid leukemia and other cancers. [...]
MNCs might have been waiting for this. After issuance of first compulsory license by Indian Patent Office to Natco from Bayer's for their drug Gleevac which is an anticancer drug, these MNC companies were already tensed that when some new generic company will rise up to the situation and file for compulsory license to [...]
Healthcare domain till recently has seen establishment of linkages to sell generic drugs by some of the Pharma giant like Piramal Healthcare Group. But ,now the latest trend & the new vision of Pharma Giant likes of Piramal Heathcare group is owning intellectual property & converting it to products.It is speculated that in many [...]
